WVE · Wave Life Sciences, Inc. · Webcasts, Transcripts & Audio
$3.13
-0.03 (-0.79%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$617.33M
Shares
197.23M
Volume · Nov 13
2.66M
Avg daily vol (3M)
3.16M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Wave Life Sciences, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Wave Life Sciences, Inc. (WVE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-27
Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript
Confident tone
WVE-007 obesity development
WVE-006 AATD clinical and regulatory progress
RNA editing platform differentiation
Revenue
$13.16M
▲ 72.9% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-10-20
Wave Life Sciences, Inc. (WVE) October 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-12
Wave Life Sciences, Inc. (WVE) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Wave Life Sciences, Inc. (WVE) Q2 2026 Earnings Call Transcript
Confident tone
WVE-007 obesity siRNA program
Phase 2A INLIGHT trial enrollment and design
WVE-006 RNA editing for AATD
Revenue
$2.27M
▼ 73.9% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Wave Life Sciences, Inc. (WVE) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Wave Life Sciences, Inc. (WVE) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-20
Wave Life Sciences, Inc. (WVE) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-28
Wave Life Sciences, Inc. (WVE) Q1 2026 Earnings Call Transcript
Confident tone
WVE-007 / INHBE obesity program
Combination and maintenance strategy in obesity
WVE-006 / AATD RNA editing
Revenue
$38.25M
▲ 316.9% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Wave Life Sciences, Inc. (WVE) Q4 2025 Earnings Call Transcript
Confident tone
WVE-007 (INHBE) for obesity
WVE-006 for AATD / RNA editing leadership
WVE-008 for PNPLA3 liver disease
Revenue
$17.25M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-12-08
Wave Life Sciences, Inc. (WVE) Q3 2025 Earnings Call Transcript
Confident tone
WVE-007 (inhibiting) obesity program
2026 clinical data catalysts
WVE-006 AATD RNA editing
Revenue
$7.61M
Diluted EPS
$-0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Wave Life Sciences, Inc. (WVE) Q2 2025 Earnings Call Transcript
Confident tone
WVE-007 / INLIGHT obesity program (INHBE siRNA)
Clinical readouts and data cadence
FORWARD-53 DMD program (WVE-N531)
Revenue
$8.70M
▼ 55.8% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Wave Life Sciences, Inc. (WVE) Q1 2025 Earnings Call Transcript
Confident tone
Obesity (WVE-007 / INHBE)
AATD / RNA Editing (WVE-006)
DMD / WVE-N531
Revenue
$9.18M
▼ 26.8% YoY Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Wave Life Sciences, Inc. (WVE) Q4 2024 Earnings Call Transcript
Confident tone
WVE-007 obesity program and GLP-1 positioning
WVE-006 AATD RNA editing program
WVE-003 Huntington's disease allele-selective program
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Wave Life Sciences, Inc. (WVE) Q3 2024 Earnings Call Transcript
Confident tone
Regulatory path and FDA interactions
DMD program WVE-N531 (FORWARD-53)
Platform differentiation and competition
Diluted EPS
$-0.47
▼ 771.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Wave Life Sciences, Inc. (WVE) Q2 2024 Earnings Call Transcript
Confident tone
WVE-003 / Huntington's disease (SELECT-HD)
WVE-007 / Obesity siRNA
WVE-006 / RNA editing for AATD
Revenue
$19.69M
▼ 10.9% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Wave Life Sciences, Inc. (WVE) Q1 2024 Earnings Call Transcript
Confident tone
RNA editing pipeline / WVE-006 (AATD)
GSK collaboration
Clinical milestones / upcoming catalysts
Revenue
$12.54M
▼ 3% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Wave Life Sciences, Inc. (WVE) Q4 2023 Earnings Call Transcript
Confident tone
INHBE obesity program
WVE-006 / AATD RNA editing program
DMD / WVE-N531 exon skipping
Revenue
$29.06M*
▲ 2245.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Wave Life Sciences, Inc. (WVE) Q3 2023 Earnings Call Transcript
Revenue
$49.21M
▲ 17168.1% YoY Diluted EPS
$0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Wave Life Sciences, Inc. (WVE) Q2 2023 Earnings Call Transcript
Revenue
$22.11M
▲ 5794.9% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Wave Life Sciences, Inc. (WVE) Q1 2023 Earnings Call Transcript
Revenue
$12.93M
▲ 638.8% YoY Diluted EPS
$-0.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-22
Wave Life Sciences, Inc. (WVE) Q4 2022 Earnings Call Transcript
Revenue
$1.24M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Wave Life Sciences, Inc. (WVE) Q3 2022 Earnings Call Transcript
Revenue
$285,000
▼ 99.2% YoY Diluted EPS
$-0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Wave Life Sciences, Inc. (WVE) Q2 2022 Earnings Call Transcript
Revenue
$375,000
▼ 86.5% YoY Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Wave Life Sciences, Inc. (WVE) Q1 2022 Earnings Call Transcript
Revenue
$1.75M
Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Wave Life Sciences, Inc. (WVE) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Wave Life Sciences, Inc. (WVE) Q3 2021 Earnings Call Transcript
Revenue
$36.42M
▲ 955.7% YoY Diluted EPS
$-0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Wave Life Sciences, Inc. (WVE) Q2 2021 Earnings Call Transcript
Revenue
$2.78M
▼ 8.3% YoY Diluted EPS
$-0.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Wave Life Sciences, Inc. (WVE) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-04
Wave Life Sciences, Inc. (WVE) Q4 2020 Earnings Call Transcript
Revenue
$9.44M*
▲ 293.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Wave Life Sciences, Inc. (WVE) Q3 2020 Earnings Call Transcript
Revenue
$3.45M
▲ 17.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Wave Life Sciences, Inc. (WVE) Q2 2020 Earnings Call Transcript
Revenue
$3.03M
▼ 60.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Wave Life Sciences, Inc. (WVE) Q1 2020 Earnings Call Transcript
Revenue
$4.16M
▲ 37.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Wave Life Sciences, Inc. (WVE) Q4 2019 Earnings Call
Revenue
$2.40M
▼ 33.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–33 of 33 webcasts
Key facts
CIK
1631574
CUSIP
94352A104
13F (30d)
161 filings
146 filers
Visit website
Investor relations